Compugen Ltd. announced that it has entered into an agreement with Baize Investments (Israel) Ltd., a private corporation investing, inter alia, in innovative medical technologies, under which it will receive $5,000,000 in R&D funding.

Under the terms of the funding agreement, which is in support of Compugen's recently announced Pipeline Programme, Baize Investments has obtained a financial interest in five designated Compugen-discovered molecules and has been issued a warrant to purchase 500,000 Compugen shares at an exercise price of $6.00 per share, expiring June 30, 2013.

Baize Investments' financial interest in the five designated molecules consists of the right to receive from Compugen up to 10 per cent of certain future payments received by Compugen from third parties in the event of the successful licensing out for development and/or commercialization of such designated Compugen molecules.

Currently, all five molecules are in active research in the company's Pipeline Programme, with their current status ranging from in silico selection to post animal model validation. In addition, the investor has the right, until June 30, 2013, to waive his right to receive all such future payments in exchange for 833,334 Compugen ordinary shares. The financial terms for the investor were established based on the assumption that any out-licensing of the designated molecules would be undertaken no later than IND filing.

Martin Gerstel, Compugen's chairman, stated, “This arrangement is an excellent example of how we can financially leverage our unique predictive product candidate discovery infrastructure to provide an increasing number of novel and attractive product candidates for potential licensing. Given the continuous expansion and improvement of this infrastructure, the in silico prediction and selection of candidates is from a practical standpoint, essentially without limit as to the number of attractive candidates that can feed our pipeline programme, and on an extremely cost-effective and systematic basis. Recently we announced the addition of twenty such novel molecules to the programme, and more have been added since that announcement. The funds received by Compugen pursuant to the agreement being announced today will allow us to pursue more aggressively our ambitious objectives for the Pipeline Program during the next few years.”

Gerstel continued, “In view of their long-term interest in the activities of the Company, we are very pleased to have Baize Investments and Murray Goldman join the Compugen team in this very meaningful endeavor.”

Murray Goldman, Baize Investments' chairman, stated, “During the past few years, we have followed Compugen's scientific progress and growing predictive discovery capabilities. We are extremely pleased to become a financial partner in advancing these exciting product candidates, all of which have the potential to address significant unmet medical needs.”

Compugen utilizes its systematic and broadly applicable predictive discovery capabilities to provide product candidates to the drug and diagnostic industries under licensing and other commercialization arrangements. During 2010, the company's pipeline programme was initiated to both expand the number of in silico predicted and selected therapeutic candidates undergoing in vitro and in vivo validation, and to significantly enhance the commercial value of Compugen's product candidate pipeline by advancing certain candidates 12-18 months beyond the successful animal disease model proof of concept stage.

In October 2010, Compugen announced that approximately 20 novel molecules had entered the pipeline programme, in addition to eight molecules that had at that time already successfully completed animal disease model or similar therapeutic proof of concept validation studies, and additional molecules have been added since then to the pipeline programme. The current areas of focus for this programme are oncology and immunology therapeutics, primarily in the form of protein, peptide and monoclonal antibody drug candidates.

Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in silico (by computer) product candidate prediction and selection utilizing a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology tools to address important unmet therapeutic and diagnostic needs – both for Compugen and its partners.